Browsing tag:

Plavix


Clopidogrel Bisulfate, also known as the brand name anticoagulant medication Plavix, continues to impress with its safety profile. A study released at the end of March 2013 revealed that patients set to undergo percutaneous coronary intervention could successfully continue their regimen of Clopidogrel during this time. Caution was extended from the study investigators, which took[…]

Read More

Known as the brand name Effient, Prasugrel was approved by the FDA in July of 2009 as a blood thinning drug. Designed to be used to reduce the risk of blood clots from forming in patients who undergo angioplasty, which is a common procedure to unblock a clogged coronary artery, Prasugrel was studied in close[…]

Read More

The FDA exclusivity for Plavix (clopidogrel) ended on May 17, 2012, while patent protection expires January 31, 2014. This exciting news brings Clopidogrel CAS# 113665-84-2, to the forefront of pharmaceutical news. With sales of Plavix generating billions of dollars for Bristol-Myers Squibb/Sanofi Pharmaceuticals, researchers are clamoring to create generic options of clopidogrel. As an antiplatelet[…]

Read More